Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

Jochen Schmitt.

Status: Completed

Conditions: Psoriasis

Treatments: Drug: Ustekinumab; Drug: Infliximab; Drug: Methotrexate; Drug: Acitretin; Drug: etanercept; Drug: fumaric acid; Drug: Adalimumab; Drug: Cyclosporins

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01812954

50310

PSO-GOE

Details and patient eligibility

About

This study is health economic analysis of medicinal treatment options for moderate-to-severe psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various different sources, including summary of product characteristics (SPCs) and the German S3 guideline on psoriasis care, health care utilization data and official statistics.

The study aims to investigate the comparative cost-effectiveness of biologic and conventional systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as well as indirect cost will be considered.

Enrollment: 1 patient

Sex: All

Ages: 16 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-diagnosis of moderate-to-severe psoriasis

Exclusion criteria